SCHEMBL21035301

SCHEMBL21035301

CSNC(=O)C(N)CCC(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.57
DPP8 Q6V1X1 4/20 0.57
DPP9 Q86TI2 4/20 0.57
BLM P54132 2/20 0.50
ALOX15 P16050 1/20 0.50
PMP22 Q01453 1/20 0.50
KMT2A Q03164 1/20 0.50
DPP7 Q9UHL4 4/20 0.33
SLC15A1 P46059 1/20 0.33
LMNA P02545 1/20 0.33
GRM8 O00222 1/20 0.33
GRM6 O15303 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GSR P00390 1/20 0.33
CYP1A2 P05177 1/20 0.33
GRIK1 P39086 1/20 0.33
GRM5 P41594 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325523 0.78 DPP4 (0.58) DPP4DPP8DPP9BLMALOX15
SCHEMBL85696 0.78 DPP4 (0.58) DPP4DPP8DPP9BLMALOX15
SCHEMBL8773315 0.77 BLM (0.60) DPP4DPP8DPP9BLMALOX15
Hydrochloric Acid SCHEMBL7509758 0.76 DPP4 (0.56) DPP4DPP8DPP9BLMALOX15
Hydrochloric Acid SCHEMBL8466590 0.76 DPP4 (0.56) DPP4DPP8DPP9BLMALOX15
SCHEMBL21034412 0.75
SCHEMBL21447963 0.75 BLM (0.58) DPP4DPP8DPP9BLMALOX15
SCHEMBL29833669 0.75 BLM (0.58) DPP4DPP8DPP9BLMALOX15
SCHEMBL288407 0.75 BLM (0.58) DPP4DPP8DPP9BLMALOX15
SCHEMBL4321248 0.75 BLM (0.58) DPP4DPP8DPP9BLMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10961189-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-03-30 US disclosed
US-20190161442-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161442-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A DPP4 2195/4885DPP8 1501/4885DPP9 2104/4885
US-10961189-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A DPP4 2195/4885DPP8 1501/4885DPP9 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.